REG - Trellus Health PLC - Issue of Equity

Trellus HealthAnnouncement

20/12/2021 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211220:nRST2495Wa&default-theme=true

RNS Number : 2495W  Trellus Health PLC  20 December 2021

Trellus Health plc

("Trellus Health" or the "Company")

 

Issue of Equity

 

LONDON, UK. AND NEW YORK, U.S. (20 December 2021). Trellus Health plc (AIM:
TRLS), which is commercialising a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces that it
has issued and allotted 33,333 ordinary shares of  0.06 pence each in the
share capital of the Company ("Ordinary Shares") following an exercise of
options. The exercise price was $0.20 per Ordinary Share.

 

Application has been made to the London Stock Exchange for the new Ordinary
Shares to be admitted to trading on AIM. It is expected that admission of the
33,333 new Ordinary Shares to trading on AIM will become effective on, or
around, 24 December 2021 ("Admission").

 

Upon Admission, the issued Ordinary Shares will rank pari passu in all
respects with the existing issued Ordinary Shares of the Company and will
trade in the Company's existing restricted line of Ordinary Shares under the
symbol TRLS and ISIN GB00BNNFM402. The Shares may not be offered or sold or
otherwise transferred in the absence of registration under the US Securities
Act, unless the transaction is exempt from, or not subject, to the
registration requirements of the US Securities Act and that resales or
reoffers of the Shares made offshore in reliance on Regulation S (of the US
Securities Act) may not be offered or sold to, or for the account or benefit
of, US Persons during the Distribution Compliance Period. Sales of existing
shares to non-US persons made in accordance with Regulation S may continue to
be made.  Further information can be found in the Company's admission
document, available via
https://trellushealth.com/investors/documents-and-presentations
(https://trellushealth.com/investors/documents-and-presentations/) .

 

Total voting rights

Following Admission, the Company will have 161,508,333 Ordinary Shares in
issue with each share carrying the right to one vote. The Company has no
Ordinary Shares held in treasury. The total number of voting rights in the
Company following Admission will therefore be 161,508,333.

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Monique Fayad, CEO                                       Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is a leading pioneer in resilience-driven care and
the first digital health company focused on the intersection of chronic
physical conditions and mental health. Trellus Health's digital-first chronic
care management solution integrates convenient access to a licensed
multidisciplinary care team with a suite of tools for resilience assessment,
education and behavior modification, remote monitoring, health maintenance and
prevention. Through its TrellusElevate™ connected care platform and
companion App, the company enables coordination and delivery of expert
whole-person care, addressing both clinical and behavioral health together, in
context, to improve outcomes and reduce healthcare costs for patients,
employers, and the healthcare system.

 

Trellus Health is commercialising the provision of digital chronic condition
management solutions for employers and health plans that utilise the
scientifically validated resilience-based methodology and a proprietary
HIPAA-compliant technology platform called TrellusElevate™ to coordinate and
deliver personalised care remotely via telehealth. The Company is initially
focused on Inflammatory bowel disease ("IBD"), which includes the chronic
incurable conditions of Crohn's Disease and ulcerative colitis, but considers
its approach to have potential utility and demand across many chronic
conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the proprietary methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. The proprietary methodology and
resilience-driven multidisciplinary care model have been scientifically
validated to demonstrate meaningful improvements in patient outcomes and over
85 per cent. reduction in unplanned healthcare utilisation (emergency
department visits and hospitalisations) which the directors of the Company
believe indicates the potential for significant cost savings for healthcare
payers.

 

The company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer,
PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT(TM )resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS.  For more information on Trellus Health,
visit www.trellushealth.com (https://trellushealth.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFESFISEFSELE